AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

Acquisition Value:
AbbVie is acquiring Aliada Therapeutics for $1.4 billion in cash.

Lead Asset:
The acquisition includes ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development to treat Alzheimer’s disease.

Technology Platform:
Aliada’s novel blood-brain barrier-crossing technology, the MODEL platform, will strengthen AbbVie’s R&D capabilities in CNS diseases.

Closing Date:
The transaction is expected to close by the end of 2024, pending regulatory approval.

Strategic Importance:
The acquisition enhances AbbVie’s neuroscience pipeline and improves its ability to deliver therapies into the central nervous system.

Legal Counsel:
Brown Rudnick provided IP counsel to Aliada Therapeutics in the acquisition process.